New Enterprise Associates
http://www.nea.com/Home/New Enterprise Associates is a venture capital firm based in Baltimore, MD. The firm has backed more than 160 companies that have gone public and invested in more than 230 companies that have been successfully merged or acquired. NEA focuses its investments in the information technology, healthcare, and energy technology industries. While NEA makes a majority of its investments in the United States, the firm invests around the world in China and India. The firm was founded in 1978.
View Older Stories View More Recent Stories
-
Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results
-
Construct Capital Closes $300 Million Fund III to Transform Foundational Industries
-
Form SCHEDULE 13D/A BuzzFeed, Inc. Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
-
Canaccord Genuity Reiterates Hold Rating on Illumina (ILMN)
-
Canaccord Genuity Reiterates Hold Rating on Illumina (ILMN)
-
Illumina (ILMN) Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors
-
Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors
-
Second Front Systems Appoints Drew Hoffman as President and Chief Legal Officer
-
Form SCHEDULE 13D/A Trevi Therapeutics, Inc. Filed by: New Enterprise Associates 16, L.P.
-
Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights
-
NeueHealth Reports Fourth Quarter and Full Year 2024 Results
-
Form SCHEDULE 13D/A BuzzFeed, Inc. Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
-
Form SCHEDULE 13D/A Senti Biosciences, Inc. Filed by: New Enterprise Associates 15, L.P.
-
Scaling its Investment Platform in Minimally Invasive Care, Intuitive Ventures Appoints Terri Burke as Senior Partner and Ross Jaffe as Venture Advisor
-
Tune Therapeutics Names John McHutchison as CEO and Chairman of the Board
-
Renata Jungo Brüngger and Lila Tretikov to be nominated to the Board of Directors at the forthcoming Annual General Meeting
-
Raise Secures $63 Million to Transform the Payments and Loyalty Industry with Blockchain-Powered Gift Cards
-
HEAVY.AI and Ookla Partner to Revolutionize Network Analytics with Unprecedented Speed and Scale
-
Form SCHEDULE 13D/A CVRx, Inc. Filed by: NEW ENTERPRISE ASSOCIATES 10 L P
-
NODAR and Leopard Imaging Announce Strategic Partnership to Showcase Advanced 3D Vision Technology at NVIDIA GTC 2025
-
Smartcar Partners with BMW Group Europe to Deliver Enhanced Connected Mobility
-
triValence Appoints Will Byington as Chief Executive Officer
-
Perceive Pharma Attracts $15M Series A Financing to Advance Ophthalmic Neuroprotection
-
Form SCHEDULE 13G/A Tuya Inc. Filed by: New Enterprise Associates 14, L.P.
-
Abcuro Announces $200 Million Series C Financing to Advance Its First-In-Class Medicine in Development for Inclusion Body Myositis
-
NEA Promotes Hunter Worland and Mustafa Neemuchwala to Principal
-
HEAVY.AI Announces Availability of Analytics Platform Accelerated by NVIDIA Grace Hopper Superchip
-
Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs
-
Aetion Appoints CEO and New Executive Chair of the Board
-
Form SCHEDULE 13D/A NEXTNAV INC. Filed by: New Enterprise Associates 14, L.P.
-
FIRE1 Secures $120 Million Financing to Revolutionize Heart Failure Care
-
Senti Biosciences (SNTI) Announces Additional $11.5M of Financing
-
Senti Bio Announces Additional $11.5 Million of Financing
-
Orbis Medicines Raises EUR 90 Million Series A Funding Round to Develop Pipeline of Oral Macrocycles
-
Novo Holdings Participates in €90 Million Series A Financing Round for Orbis Medicines to Support Development of Oral Macrocycle Drugs
-
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: MoneyLion Inc. (NYSE - ML), Marinus Pharmaceuticals, Inc. (Nasdaq - MRNS), Better Choice Inc. (NYSE American -
-
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating NeueHealth, Inc. Buyout
-
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of NeueHealth, Inc. (NEUE)
-
Form SCHEDULE 13D/A NeueHealth, Inc. Filed by: New Enterprise Associates 17, L.P.
-
Wall Street ends higher as Santa rally begins
-
NeueHealth to Be Taken Private by NEA and Consortium of Investors
-
Form SCHEDULE 13D/A Marker Therapeutics, Filed by: New Enterprise Associates 16, L.P.
-
Marker Therapeutics (MRKR) Announces $16.1 Million Private Placement
-
Marker Therapeutics Announces $16.1 Million Private Placement
-
Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million
-
Form SC 13D/A Senti Biosciences, Inc. Filed by: New Enterprise Associates 15, L.P.
-
Senti Biosciences (SNTI) Announces Oversubscribed $37.6 Million Private Placement Equity Financing
-
Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing
-
Brenig Therapeutics Announces the Initiation of First-in-Human Clinical Trial of BT-267, a Best-in-Class LRRK2 Inhibitor for Parkinson's Disease
-
SpyGlass Pharma Completes Enrollment in Phase I/II Study of its Promising Long-Term Drug Delivery Platform for Glaucoma and Ocular Hypertension

